Literature DB >> 28673684

The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.

J D Schumacher1, B Kong1, Y Pan2, L Zhan3, R Sun2, J Aa2, D Rizzolo1, J R Richardson1, A Chen4, M Goedken1, L M Aleksunes1, D L Laskin1, G L Guo5.   

Abstract

Non-alcoholic steatohepatitis (NASH) is a form of non-alcoholic fatty liver disease (NAFLD) characterized by steatosis, inflammation, and fibrosis often associated with metabolic syndrome. Fibroblast growth factor 15 (FGF15), an endocrine factor mainly produced in the distal part of small intestine, has emerged to be a critical factor in regulating bile acid homeostasis, energy metabolism, and liver regeneration. We hypothesized that FGF15 alters the development of each of the listed features of NASH. To test this hypothesis, four-week old male Fgf15-/- and their corresponding wild-type (WT) mice were fed either a high fat diet (HFD) or a control chow diet for six months. The results confirmed that HFD feeding for six months in WT mice recapitulated human NASH phenotype, including macrovesicular steatosis, inflammation, and fibrosis. Whereas FGF15 deficiency had no effect on the severity of liver steatosis or inflammation, it was associated with decreased liver fibrosis. Furthermore, FGF15 deficiency resulted in abnormal bile acid homeostasis, increased insulin resistance, increased HFD-induced serum triglycerides, decreased inductions of hepatic cholesterol content by HFD, and altered gene expression of lipid metabolic enzymes. These data suggest that FGF15 improves lipid homeostasis and reduces bile acid synthesis, but promotes fibrosis during the development of NASH.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bile acids; Fibroblast growth factor 15; Fibrosis; Metabolic syndrome; Non-alcoholic steatohepatitis

Mesh:

Substances:

Year:  2017        PMID: 28673684      PMCID: PMC5812273          DOI: 10.1016/j.taap.2017.06.023

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  28 in total

Review 1.  NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages.

Authors:  Veerle Bieghs; Patrick C N Rensen; Marten H Hofker; Ronit Shiri-Sverdlov
Journal:  Atherosclerosis       Date:  2011-09-03       Impact factor: 5.162

2.  Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog.

Authors:  A G Baillie; C T Coburn; N A Abumrad
Journal:  J Membr Biol       Date:  1996-09       Impact factor: 1.843

3.  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors:  Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

4.  Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL.

Authors:  D Calvo; D Gómez-Coronado; Y Suárez; M A Lasunción; M A Vega
Journal:  J Lipid Res       Date:  1998-04       Impact factor: 5.922

5.  Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice.

Authors:  Iker Uriarte; Maite G Fernandez-Barrena; Maria J Monte; Maria U Latasa; Haisul C Y Chang; Simone Carotti; Umberto Vespasiani-Gentilucci; Sergio Morini; Eva Vicente; Axel R Concepcion; Juan F Medina; José Juan G Marin; Carmen Berasain; Jesus Prieto; Matías A Avila
Journal:  Gut       Date:  2013-01-03       Impact factor: 23.059

6.  Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway.

Authors:  Yue-Feng Shi; Chi-Chun Fong; Qi Zhang; Pik-Yuen Cheung; Chi-Hung Tzang; Rudolf S S Wu; Mengsu Yang
Journal:  FEBS Lett       Date:  2006-12-13       Impact factor: 4.124

7.  FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4.

Authors:  M H Xie; I Holcomb; B Deuel; P Dowd; A Huang; A Vagts; J Foster; J Liang; J Brush; Q Gu; K Hillan; A Goddard; A L Gurney
Journal:  Cytokine       Date:  1999-10       Impact factor: 3.861

8.  Liver-specific activities of FGF19 require Klotho beta.

Authors:  Benjamin C Lin; Manping Wang; Craig Blackmore; Luc R Desnoyers
Journal:  J Biol Chem       Date:  2007-07-11       Impact factor: 5.157

9.  FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.

Authors:  Serkan Kir; Sara A Beddow; Varman T Samuel; Paul Miller; Stephen F Previs; Kelly Suino-Powell; H Eric Xu; Gerald I Shulman; Steven A Kliewer; David J Mangelsdorf
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Authors:  Kristine A Drafahl; Christopher W McAndrew; April N Meyer; Martin Haas; Daniel J Donoghue
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

View more
  19 in total

1.  Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export.

Authors:  Fawzi Alogaili; Sivaprakasam Chinnarasu; Anja Jaeschke; Evangelia G Kranias; David Y Hui
Journal:  J Biol Chem       Date:  2020-02-20       Impact factor: 5.157

2.  Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.

Authors:  Justin D Schumacher; Bo Kong; Jason Wu; Daniel Rizzolo; Laura E Armstrong; Monica D Chow; Michael Goedken; Yi-Horng Lee; Grace L Guo
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

Review 3.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

4.  Fibroblast Growth Factor 15-Dependent and Bile Acid-Independent Promotion of Liver Regeneration in Mice.

Authors:  Bo Kong; Runbin Sun; Mingxing Huang; Monica D Chow; Xiao-Bo Zhong; Wen Xie; Yi-Horng Lee; Grace L Guo
Journal:  Hepatology       Date:  2018-10-08       Impact factor: 17.425

5.  Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.

Authors:  Sangwon Byun; Hyunkyung Jung; Jinjing Chen; Young-Chae Kim; Dong-Hyun Kim; Bo Kong; Grace Guo; Byron Kemper; Jongsook Kim Kemper
Journal:  J Biol Chem       Date:  2019-04-17       Impact factor: 5.157

Review 6.  Fibroblast growth factor 15/19 expression, regulation, and function: An overview.

Authors:  Greg Guthrie; Caitlin Vonderohe; Douglas Burrin
Journal:  Mol Cell Endocrinol       Date:  2022-03-15       Impact factor: 4.369

7.  Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice.

Authors:  Rachel M Golonka; Beng San Yeoh; Yaqi Li; Piu Saha; Ahmed A Abokor; Xi Cheng; Xia Xiao; Darshan Shimoga Chandrashekar; Sooryanarayana Varambally; David J Gonzalez; A Catharine Ross; Matam Vijay-Kumar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-03-23       Impact factor: 4.052

8.  Assessment of the role of FGF15 in mediating the metabolic outcomes of murine Vertical Sleeve Gastrectomy (VSG).

Authors:  Andriy Myronovych; Jashdeep Bhattacharjee; Rosa-Maria Salazar-Gonzalez; Brandon Tan; Sarah Mowery; Danielle Ferguson; Karen K Ryan; Wujuan Zhang; Xueheng Zhao; Melissa Oehrle; Kenneth Dr Setchell; Randy J Seeley; Darleen A Sandoval; Rohit Kohli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-09-23       Impact factor: 4.052

Review 9.  Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation.

Authors:  Li Qi; Wanlin Dai; Jing Kong; Yu Tian; Yongsheng Chen
Journal:  J Physiol Biochem       Date:  2021-07-24       Impact factor: 4.158

10.  Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity.

Authors:  Joanne M Donkers; Reinout L P Roscam Abbing; Michel van Weeghel; Johannes H M Levels; Anita Boelen; Alfred H Schinkel; Ronald P J Oude Elferink; Stan F J van de Graaf
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.